cxcl11.1 Antibody

What is CXCL11 and what is its biological significance?

CXCL11, also known as Interferon-inducible T-cell alpha chemoattractant (I-TAC), is a member of the ELR-negative CXC chemokine family. It functions primarily as a chemotactic factor for interleukin-activated T-cells, but notably does not attract unstimulated T-cells, neutrophils, or monocytes. CXCL11 induces calcium release in activated T-cells by binding to the CXCR3 and CXCR7 receptors. This chemokine plays significant roles in T-cell recruitment to sites of inflammation, particularly in CNS diseases and skin immune responses. Its production is stimulated by interferons in various cells including leukocytes, fibroblasts, and endothelial cells. The biological significance of CXCL11 extends to chemotactic migration, regulation of cell proliferation and self-renewal, and enhancement of cell adhesion .

How do I select the appropriate CXCL11 antibody for my research?

Selecting the appropriate CXCL11 antibody depends on several experimental factors. First, consider the specific application requirements - different antibodies are optimized for Western blot (WB), immunohistochemistry (IHC), immunoprecipitation (IP), or ELISA applications. For instance, the 10707-1-AP antibody from Proteintech is validated for WB, IHC, and ELISA applications with human samples, while Abcam's EPR21755-173 antibody (ab216157) is recommended for IP and WB applications. Second, evaluate the antibody's specificity and host species compatibility with your experimental system. The antibody should react with your species of interest (human samples for both antibodies mentioned in the search results). Third, consider the antibody type - polyclonal antibodies like 10707-1-AP offer broad epitope recognition, while monoclonal recombinant antibodies like EPR21755-173 provide higher specificity and reproducibility. Finally, review validation data and published applications to ensure reliability for your specific research context .

What are the optimal conditions for using CXCL11 antibodies in Western blot applications?

For optimal Western blot applications with CXCL11 antibodies, researchers should follow specific technical parameters. The recommended dilution range for the Proteintech 10707-1-AP antibody is 1:500-1:1000, while specific dilution information for Abcam's antibody should be determined experimentally. Sample preparation is crucial; for CXCL11 detection, stimulating cells with interferon-gamma, LPS, and Brefeldin A (as demonstrated with THP-1 cells) significantly enhances detectable expression. A 5% non-fat dry milk in TBST is recommended as blocking/dilution buffer. When visualizing results using ECL technique, relatively short exposure times (approximately 30 seconds) may be sufficient. Researchers should anticipate a band at approximately 10-11 kDa and may need to optimize conditions for their specific sample types. Additionally, it's essential to include appropriate positive controls, such as IFN-gamma-treated cells, and negative controls to confirm antibody specificity .

How should I optimize CXCL11 antibody use for immunohistochemistry?

For immunohistochemistry (IHC) applications with CXCL11 antibodies, several optimization steps are critical. The Proteintech 10707-1-AP antibody is recommended at a dilution range of 1:50-1:500 for IHC applications. Antigen retrieval is a crucial step; the suggested method involves using TE buffer at pH 9.0, though citrate buffer at pH 6.0 may serve as an alternative. Human colon cancer tissue has been validated as a positive control for IHC applications with this antibody. For optimal results, researchers should:

• Perform preliminary titration experiments to determine the ideal antibody concentration for their specific tissue type

• Include positive control tissues (like human colon cancer) in each experiment

• Compare multiple antigen retrieval methods if initial results are suboptimal

• Consider tissue-specific fixation times and processing methods, as these can significantly impact epitope accessibility

• Optimize incubation times and temperatures based on signal-to-noise ratios

Sample-dependent variations are common, so consulting the validation data gallery provided by the manufacturer is recommended for tissue-specific optimization strategies .

What cell types and tissues are most appropriate for studying CXCL11 expression?

The most appropriate cell types and tissues for studying CXCL11 expression depend on research objectives, but several systems have been well-validated. For in vitro studies, THP-1 cells treated with IFN-gamma, LPS, and Brefeldin A provide a reliable positive control for CXCL11 expression. These treatments mimic inflammatory conditions that naturally induce CXCL11. For tissue analysis, human colon cancer tissue has been validated for IHC applications with CXCL11 antibodies. Based on comprehensive pan-cancer analysis, CXCL11 expression is significantly upregulated in multiple cancer types compared to corresponding normal tissues, particularly in BLCA (bladder), BRCA (breast), CHOL (cholangiocarcinoma), COAD (colon), ESCA (esophageal), HNSC (head and neck), KICH (kidney chromophobe), KIRC (kidney renal clear cell), PRAD (prostate), READ (rectal), and STAD (stomach) cancers. These cancer types may be particularly valuable for studying CXCL11's role in tumor immune responses. For research focusing on immune cell recruitment, tissues with high T-cell infiltration would be most informative, as CXCL11 specifically attracts activated T-cells .

How does CXCL11 expression correlate with immune cell infiltration in different cancer types?

CXCL11 expression demonstrates significant associations with immune cell infiltration across various cancer types, with notable patterns emerging from comprehensive analyses. Based on data from the TIMER 2.0 database, CXCL11 expression shows a consistent positive correlation with CD8+ T cells and T follicular helper cells in almost all cancer types examined. This supports CXCL11's established role as a T-cell chemoattractant. Conversely, CXCL11 expression negatively correlates with myeloid-derived suppressor cells (MDSCs) across multiple cancers, suggesting a potential counterregulatory relationship.

The strength of these correlations varies by cancer type, with particularly strong associations observed in skin cutaneous melanoma (SKCM), thyroid cancer (THCA), and cholangiocarcinoma (CHOL). These findings align with CXCL11's functional role in recruiting activated T cells to sites of inflammation, including the tumor microenvironment. Mechanistically, this suggests that CXCL11 may contribute to antitumor immunity by promoting effector T-cell infiltration into tumors, a critical factor for successful immunotherapy responses .

What is the relationship between CXCL11 expression and tumor mutation burden (TMB) or microsatellite instability (MSI)?

CXCL11 expression shows significant associations with both tumor mutation burden (TMB) and microsatellite instability (MSI), two important biomarkers for immunotherapy response. High CXCL11 expression positively correlates with increased TMB in multiple cancer types, including BLCA (bladder), BRCA (breast), CESC (cervical), COAD (colon), LGG (lower-grade glioma), LUAD (lung adenocarcinoma), OV (ovarian), SKCM (melanoma), STAD (stomach), THYM (thymoma), and UCEC (endometrial). This positive correlation is particularly noteworthy as higher TMB often predicts better responses to immune checkpoint inhibitors.

Regarding MSI, positive correlations with CXCL11 expression were specifically identified in COAD (colon adenocarcinoma) and UVM (uveal melanoma). Since MSI is an established biomarker for predicting response to PD-1 therapy, these correlations suggest CXCL11 may serve as a surrogate marker for identifying patients likely to benefit from immunotherapy in these specific cancer types. The relationship between CXCL11 and these genomic features provides mechanistic insights into how CXCL11 might influence the tumor immune microenvironment and suggests its potential utility as a complementary biomarker for immunotherapy response prediction .

How is CXCL11 expression related to tumor microenvironment (TME) scores?

CXCL11 expression demonstrates significant correlations with various tumor microenvironment (TME) scores across multiple cancer types. Spearman's correlation analysis reveals that CXCL11 expression positively associates with ImmuneScore, StromalScore, and EstimateScore in the majority of cancers studied. These correlations are particularly strong in cholangiocarcinoma (CHOL), skin cutaneous melanoma (SKCM), and thyroid cancer (THCA).

The positive correlation with ImmuneScore indicates that higher CXCL11 expression is associated with increased immune cell infiltration in the tumor microenvironment. Similarly, the positive correlation with StromalScore suggests an association between CXCL11 expression and the presence of stromal cells within the tumor. The EstimateScore, which combines both immune and stromal components, also shows positive correlation with CXCL11 expression.

These findings suggest that CXCL11 plays a significant role in shaping the tumor microenvironment, potentially by recruiting immune cells, particularly T cells, to the tumor site. This relationship with TME components further supports CXCL11's potential as a biomarker for immunotherapy response, as a favorable TME is often associated with better outcomes to immune checkpoint inhibitors .

What are common technical challenges when using CXCL11 antibodies in experimental settings?

Researchers frequently encounter several technical challenges when working with CXCL11 antibodies. First, detecting endogenous CXCL11 can be difficult due to its relatively low basal expression in many cell types; stimulation with IFN-gamma, LPS, and Brefeldin A is often necessary to induce detectable expression levels, particularly in THP-1 cells. Second, antibody specificity may be a concern, as CXCL11 shares structural similarities with other CXC chemokines; careful validation is essential to ensure specific detection of CXCL11 rather than related proteins. Third, post-translational modifications can affect epitope recognition, potentially causing inconsistent results between different experimental approaches. Fourth, sample processing methods significantly impact results - for IHC applications, antigen retrieval methods are particularly critical, with TE buffer at pH 9.0 recommended but citrate buffer at pH 6.0 as an alternative. Finally, storage conditions affect antibody performance; the recommended storage is at -20°C, with stability guaranteed for one year after shipment. For 20μl sizes containing 0.1% BSA, aliquoting is considered unnecessary for -20°C storage, but larger volumes may benefit from aliquoting to minimize freeze-thaw cycles .

How can researchers validate the specificity of CXCL11 antibodies?

Validating antibody specificity is critical for reliable CXCL11 research. A comprehensive validation approach should include multiple complementary methods:

• Positive and negative controls: Utilize known CXCL11-expressing samples (e.g., IFN-gamma/LPS/Brefeldin A-treated THP-1 cells) as positive controls and untreated cells as negative controls. The dramatic difference in expression creates a clear specificity benchmark.

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight of approximately 10-11 kDa in Western blot applications. Significant deviations may indicate non-specific binding.

• Expression pattern comparison: Compare observed expression patterns with published literature (e.g., PMID: 17142784) to verify consistency across independent studies.

• Multiple application validation: Test the antibody in different applications (WB, IHC, IP) to confirm consistent target recognition across techniques.

• Peptide competition assay: Pre-incubate the antibody with purified CXCL11 protein or immunogenic peptide; this should block specific binding and eliminate true positive signals.

• Genetic approaches: Use CXCL11 knockdown/knockout systems to confirm signal reduction/elimination with reduced target expression.

• Multiple antibody validation: Compare results using antibodies targeting different CXCL11 epitopes to confirm consistent detection patterns.

For definitive validation in critical research, combining multiple approaches provides the strongest evidence of antibody specificity .

What optimization strategies are recommended for detecting low CXCL11 expression levels?

Detecting low CXCL11 expression levels requires specialized optimization strategies across different experimental platforms. For Western blot applications, researchers should first consider cellular stimulation - treating cells with IFN-gamma, LPS, and Brefeldin A substantially increases CXCL11 expression in models like THP-1 cells. Technically, using higher antibody concentrations (toward the 1:500 end of the recommended 1:500-1:1000 range) may enhance sensitivity, though this adjustment must balance with potential increased background. Enhanced chemiluminescence (ECL) detection systems with extended exposure times beyond the standard 30 seconds may reveal faint bands, though increasing exposure beyond 2-3 minutes risks detecting non-specific signals.

For IHC applications on tissues with low CXCL11 expression, optimization of antigen retrieval is particularly critical. While TE buffer at pH 9.0 is generally recommended, some epitopes may be better exposed using citrate buffer at pH 6.0. Signal amplification systems like tyramide signal amplification (TSA) can significantly enhance detection sensitivity. Additionally, extending primary antibody incubation time (overnight at 4°C rather than standard shorter incubations) often improves detection of low-abundance proteins without proportionally increasing background.

For all applications, reducing background through optimized blocking (5% NFDM/TBST is recommended) and including appropriate negative controls is essential for distinguishing true low-level signals from experimental noise .

How does CXCL11 expression influence patient prognosis across different cancer types?

Some cancer types show a positive association between high CXCL11 expression and improved patient outcomes, potentially reflecting enhanced anti-tumor immune responses mediated by increased T-cell infiltration. Conversely, other cancer types demonstrate negative associations, where high CXCL11 expression correlates with poorer outcomes. This heterogeneity likely reflects the complex, context-dependent role of CXCL11 and the immune response in different tumor microenvironments.

Time-dependent receiver operating characteristic (ROC) curve analysis further confirms the variable prognostic value of CXCL11 across different cancers. These findings emphasize the importance of considering cancer type when evaluating CXCL11 as a prognostic biomarker, suggesting that its clinical utility may be limited to specific cancer types where consistent associations are observed .

How is CXCL11 related to immune checkpoint molecules and potential immunotherapy response?

CXCL11 demonstrates significant associations with multiple immune checkpoint molecules across various cancer types, suggesting its potential relevance for immunotherapy response prediction. Analysis reveals that increased CXCL11 expression positively correlates with the expression of numerous immunosuppressive factors in almost all cancer types studied, with the notable exception of thymoma (THYM). Similarly, CXCL11 expression shows positive associations with most immunostimulatory genes across the cancer spectrum, again with THYM being an exception.

These correlations have important implications for immunotherapy. The positive relationship between CXCL11 and CD8+ T cell infiltration, combined with its correlation with immune checkpoint molecules, suggests that CXCL11 may serve as a marker for "hot" tumor immune microenvironments that are potentially more responsive to immune checkpoint inhibitors. Additionally, the positive correlations between CXCL11 expression and TMB (tumor mutation burden) in multiple cancer types, including BLCA, BRCA, CESC, COAD, LGG, LUAD, OV, SKCM, STAD, THYM, and UCEC, further strengthen this potential connection, as higher TMB often predicts better responses to immunotherapy.

The observed correlations between CXCL11 and MSI (microsatellite instability) in COAD and UVM provide additional evidence for CXCL11's potential role in identifying immunotherapy-responsive tumors, as MSI is an established biomarker for PD-1 therapy response. Together, these findings suggest that CXCL11 could serve as a complementary biomarker for immunotherapy response prediction, potentially helping to identify patients most likely to benefit from immune checkpoint blockade .

What functional pathways are associated with CXCL11 expression in cancer?

Functional analysis of CXCL11 expression across cancer types reveals significant associations with immune-relevant pathways. Elevated CXCL11 expression consistently correlates with the activation of pathways involved in immune response and inflammation. This is evidenced by the positive correlation between CXCL11 expression and various immune-related genes, including chemokine receptors, other chemokines, immunostimulatory genes, immunosuppressive genes, and MHC genes across most cancer types.

Specifically, CXCL11 shows strong positive correlations with almost all chemokine receptors in most cancers except acute myeloid leukemia (LAML), with particularly strong associations observed for all chemokine receptors except CXCR1 and CCR10. Similarly, CXCL11 expression positively correlates with most other chemokines, with exceptions being CCL14, CCL15, CCL16, CCL27, CCL28, CXCL6, and CXCL17.

The relationship extends to MHC genes, where CXCL11 expression positively correlates with all MHC genes in most cancers except diffuse large B-cell lymphoma (DLBC). These comprehensive correlations suggest that CXCL11 functions within a broader network of immune signaling pathways, potentially influencing T-cell recruitment, activation, and function within the tumor microenvironment.

The consistent association with immune-relevant pathways across multiple cancer types supports CXCL11's role as a potential biomarker for immunologically active tumors and further suggests that therapeutic strategies targeting CXCL11 or its associated pathways might enhance anti-tumor immune responses .

What are the recommended storage and handling conditions for CXCL11 antibodies?

When handling the antibodies, researchers should follow general antibody care guidelines: minimize exposure to room temperature, avoid repeated freeze-thaw cycles, and ensure sterile technique to prevent contamination. For dilution and application, 5% non-fat dry milk in TBST is recommended as a blocking/dilution buffer for Western blot applications. It's important to note that sodium azide in the storage buffer is incompatible with horseradish peroxidase conjugates, so antibody dilutions for immunohistochemical applications should be prepared in buffers without sodium azide when using HRP-based detection systems .

What experimental controls are essential when working with CXCL11 antibodies?

When working with CXCL11 antibodies, several essential experimental controls should be incorporated to ensure reliable and interpretable results:

• Positive Controls:

  • For Western blot: IFN-gamma, LPS and Brefeldin A-treated THP-1 cells have been validated as positive controls

  • For IHC: Human colon cancer tissue has been confirmed as an appropriate positive control

• Negative Controls:

  • Isotype controls: Include rabbit IgG (for 10707-1-AP antibody) at matching concentrations to identify non-specific binding

  • Untreated cell lysates to contrast with stimulated samples

  • Normal tissue adjacent to tumor tissue in IHC applications

• Technical Controls:

  • Loading controls for Western blot (β-actin, GAPDH, etc.) to normalize protein quantities

  • Multiple dilutions of primary antibody to establish optimal signal-to-noise ratio

  • Antigen retrieval controls when performing IHC (samples with and without antigen retrieval)

• Specificity Controls:

  • Peptide competition assays to confirm signal specificity

  • Parallel experiments with antibodies targeting different CXCL11 epitopes

  • Genetic knockdown/knockout samples when available

• Application-Specific Controls:

  • For quantitative analyses, include a standard curve of recombinant CXCL11 protein

  • For tissue analysis, include multiple tissue types including those known to express high and low CXCL11 levels

Implementing these controls helps distinguish specific from non-specific signals and provides crucial context for interpreting experimental results .

What bioinformatic approaches are recommended for analyzing CXCL11 expression in public datasets?

For comprehensive analysis of CXCL11 expression in public datasets, several bioinformatic approaches are recommended based on successful implementations in published research:

• Data Acquisition and Normalization:

  • Integrate data from complementary databases like TCGA (The Cancer Genome Atlas) and GTEx (Genotype-Tissue Expression) for comprehensive coverage of tumor and normal tissues

  • Normalize expression data using log2 [TPM (Transcripts per million) +1] transformation to facilitate cross-dataset comparisons

  • Access data through platforms like UCSC Xena (http://xena.ucsc.edu/) or directly from original databases (https://portal.gdc.cancer.gov/ and https://www.gtexportal.org/home/)

• Differential Expression Analysis:

  • For comparison between tumor and normal tissues, apply Student's t-test for paired comparisons

  • For multi-group comparisons, use Kruskal-Wallis test (non-parametric) or one-way ANOVA (parametric) depending on data distribution

  • Consider p < 0.05 as the significance threshold for differential expression

• Survival Analysis:

  • Implement Kaplan-Meier analysis with log-rank tests to evaluate survival differences between high and low CXCL11 expression groups

  • Apply univariate Cox proportional hazards regression to quantify associations with survival outcomes (OS, DSS, DFI, PFI)

  • Generate time-dependent ROC curves to assess predictive accuracy

  • Report hazard ratios (HR) with 95% confidence intervals (CI)

• Correlation Analysis:

  • Use Spearman's rank correlation coefficient to analyze associations between CXCL11 expression and continuous variables (TMB, MSI, immune scores)

  • For immune infiltration analysis, utilize specialized tools like TIMER 2.0

  • Create correlation heatmaps to visualize relationships between CXCL11 and other immune-related genes

• Software Recommendations:

  • R software (Version 4.1.3 or later) with specialized packages:

    • survival and survminer for survival analysis

    • rms for time-dependent ROC curves

    • ggplot2 for visualization

This methodological framework provides a robust approach for comprehensive characterization of CXCL11 expression patterns and their clinical/biological implications across cancer types .

What are the most promising research directions for CXCL11 antibodies in cancer immunotherapy?

The most promising research directions for CXCL11 antibodies in cancer immunotherapy stem from emerging patterns in current data. First, exploring the therapeutic potential of modulating CXCL11 signaling represents a significant opportunity. Given the positive correlation between CXCL11 expression and CD8+ T cell infiltration in multiple cancer types, strategies that enhance CXCL11 signaling might improve T cell recruitment to tumors, potentially augmenting responses to existing immunotherapies like checkpoint inhibitors. Conversely, in contexts where CXCL11 may promote tumor progression, blocking antibodies could offer therapeutic benefit.

Second, developing CXCL11 as a predictive biomarker for immunotherapy response merits further investigation. The established correlations between CXCL11 expression and TMB, MSI, and immune cell infiltration suggest its potential utility in identifying patients likely to benefit from immunotherapy. Prospective studies evaluating baseline CXCL11 levels in relation to treatment outcomes could validate this approach.

Third, investigating the impact of CXCL11 on different immune cell populations beyond CD8+ T cells and T follicular helper cells could uncover additional mechanisms influencing the tumor microenvironment. This includes examining how CXCL11 affects regulatory T cells, myeloid-derived suppressor cells, and antigen-presenting cells.

Finally, developing improved CXCL11 antibodies with enhanced specificity, sensitivity, and performance across multiple applications would facilitate more robust research in this field. This includes engineering antibodies capable of distinguishing between different post-translationally modified forms of CXCL11, which might exhibit distinct biological activities .

What methodological advances would improve CXCL11 detection and quantification?

Several methodological advances could significantly enhance CXCL11 detection and quantification in research settings. First, developing multiplex immunoassays that simultaneously detect CXCL11 alongside other chemokines and cytokines would provide more comprehensive insights into immune signaling networks. This approach would be particularly valuable given CXCL11's functional relationships with other chemokines and immune modulators.

Second, advancing single-cell technologies for CXCL11 detection would enable researchers to identify specific cellular sources and targets of CXCL11 within heterogeneous tissues. Combining single-cell RNA sequencing with protein-level detection methods could reveal crucial details about CXCL11's role in cell-cell communication within the tumor microenvironment.

Third, creating improved in situ detection methods with enhanced sensitivity would facilitate better visualization of CXCL11 distribution in tissue contexts. This includes developing RNAscope protocols specific for CXCL11 mRNA and optimizing multiplexed immunofluorescence approaches for simultaneous detection of CXCL11 and its receptors.

Fourth, standardizing quantification methods across laboratories would improve data comparability. Establishing universal reference standards and validated protocols for CXCL11 quantification in different sample types (serum, tissue lysates, cell culture supernatants) would address current challenges in cross-study comparisons.

Finally, developing computational tools specifically designed for analyzing spatial relationships between CXCL11 expression and immune cell infiltration patterns would enhance our understanding of how CXCL11 gradients influence immune cell trafficking within tissues. These approaches would collectively advance our ability to accurately detect, quantify, and interpret CXCL11 expression in complex biological systems .

How might CXCL11 research contribute to personalized medicine approaches?

CXCL11 research holds significant potential to contribute to personalized medicine approaches in several key ways. First, as a potential predictive biomarker for immunotherapy response, CXCL11 expression analysis could help stratify patients based on likelihood of benefit from immune checkpoint inhibitors. The established correlations between CXCL11 expression and factors associated with immunotherapy response (TMB, MSI, CD8+ T cell infiltration) provide a strong rationale for incorporating CXCL11 assessment into patient selection strategies.

Second, the cancer type-specific associations between CXCL11 expression and patient outcomes suggest that its utility as a prognostic marker may be context-dependent. This highlights the importance of cancer-specific approaches to biomarker implementation, where CXCL11 assessment might be particularly valuable in certain cancer types while less informative in others.

Third, understanding the relationship between CXCL11 and the tumor immune microenvironment could inform combination therapy strategies. For instance, patients with low CXCL11 expression might benefit from approaches that enhance T cell recruitment to tumors, while those with high expression but poor outcomes might require interventions targeting immunosuppressive mechanisms.

Fourth, monitoring CXCL11 levels during treatment could provide dynamic information about evolving immune responses. Changes in CXCL11 expression might serve as an early indicator of treatment efficacy or resistance, enabling timely therapeutic adjustments.